clerotherapy is a venous ablation technique used to manage chronic venous insufficiency, particularly in varicose veins, reticular veins, and telangiectasias.
1
A potential complication of foam sclerotherapy is the formation of gas microemboli in the brain, which can lead to neurologic deficits. 2, 3 In a study of 1025 patients who underwent sclerotherapy, 2.6% reported visual disturbances, migraines, or transient ischemic attacks (TIAs) developing after the procedure. 1 A study of 500 patients reported the incidence of transient visual disturbances after sclerotherapy as 0.09% to 2.0%, with most cases involving foam sclerotherapy. 3 We present a case of neurologic sequelae after foam sclerotherapy in a patient with an undiagnosed patent foramen ovale (PFO). In patients with PFO, when the pressure in the right atrium increases, such as with the Valsalva maneuver, an asymptomatic PFO may open, thus increasing the risk of microemboli traveling into the left atrium and then traveling systemically.
Report of Case
A 55-year-old woman presented to the emergency department with visual disturbances, confusion, and dysarthria. Earlier in the day, she had undergone foam sclerotherapy, with no apparent complications. She noticed her symptoms while driving home after the procedure, which prompted her to return to the hospital. All of the symptoms resolved within 30 minutes of onset. Before the procedure, her medical and social history were found to be unremarkable aside from self-reported migraines.
Her family history did not indicate that she was at risk for thrombus formation or other contraindications for the procedure. She was taking ibuprofen as needed and levothyroxine for hypothyroidism.
In the emergency department, the patient was Migraine headaches and heart defects, such as a PFO, put patients at risk for microembolisms leading to TIAs or other neurologic conditions. 4 The existence of a PFO could be unknown in a large number of patients, as it is largely asymptomatic. 5 An autopsy study of 965 hearts from cadavers evenly distributed in age and sex showed the existence of a PFO in 25% to 30% of the hearts. 5 The rather high incidence of PFO suggests the need to screen patients for PFO before sclerotherapy given the risks for neurologic sequelae. One study 6 examined cerebrovascular gas microemboli in 82 patients undergoing foam sclerotherapy.
The patients were monitored with transcranial Doppler ultrasonography, and within 15 minutes of the procedure, a right-to-left shunt developed in 61 patients, allowing gas microemboli to flow into the middle cerebral artery. 7 Knowledge of a PFO would allow proper guidance for patients who are consid- 
Conclusion
With the rise in popularity of foam sclerotherapy, it benefits physicians and patients to understand the risks of neurologic sequelae after this procedure. Our patient did not have obvious risk factors for complications of the procedure; however, she had visual and neurologic disturbances shortly after the procedure.
It may be beneficial, therefore, to monitor patients for any symptoms before discharge from the medical office. Because neurologic complications are relatively rare, screening all patients for PFO may not be justified; however, a discussion with patients about potential complications may be warranted. Educating patients on stroke signs and symptoms and contraindications such as a PFO as a part of informed consent, for example, should be communicated in case a patient has an undiagnosed PFO or another undiagnosed risk factor that could lead to complications from foam sclerotherapy.
